Abstract
Pentosan polysulphate, delivered by chronic intraventricular infusion, has been proposed as a potential therapy for human prion disease. The first treated patient is still alive several years after treatment started. Here we describe in detail a case of variant Creutzfeldt-Jakob disease in which this treatment was started at a relatively early stage but had no definite clinical benefit. The patient died from disease progression 16 months after diagnosis and 5 months after pentosan polysulphate treatment was commenced.
MeSH terms
-
Adult
-
Akinetic Mutism / etiology
-
Akinetic Mutism / physiopathology
-
Biopsy
-
Brain / drug effects*
-
Brain / pathology*
-
Brain / physiopathology
-
Cognition Disorders / etiology
-
Cognition Disorders / physiopathology
-
Creutzfeldt-Jakob Syndrome / drug therapy*
-
Creutzfeldt-Jakob Syndrome / physiopathology
-
Creutzfeldt-Jakob Syndrome / psychology
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / administration & dosage
-
Fatal Outcome
-
Female
-
Gait Ataxia / etiology
-
Gait Ataxia / physiopathology
-
Humans
-
Infusion Pumps, Implantable
-
Injections, Intraventricular
-
Magnetic Resonance Imaging
-
Mental Disorders / etiology
-
Mental Disorders / physiopathology
-
Palatine Tonsil / metabolism
-
Palatine Tonsil / physiopathology
-
Pentosan Sulfuric Polyester / administration & dosage*
-
Prions / analysis
-
Prions / metabolism
-
Seizures / etiology
-
Seizures / physiopathology
-
Treatment Failure
Substances
-
Enzyme Inhibitors
-
Prions
-
Pentosan Sulfuric Polyester